NDAORALFOR SUSPENSION
Approved
Jun 2013
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZEGERID OTC is an over-the-counter oral suspension combining omeprazole (a proton pump inhibitor) with sodium bicarbonate to provide rapid acid neutralization and sustained acid suppression. It is indicated for the short-term treatment of frequent heartburn and acid reflux in adults. The sodium bicarbonate component allows faster onset of action compared to omeprazole alone, making it attractive for symptomatic relief.
Peak
Product is in peak lifecycle stage but moderate competitive pressure (30) suggests mature market positioning with potential revenue stability for established brand teams.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ZEGERID OTC offers exposure to OTC commercial strategy, competitive positioning, and market defense in a mature category. Career value lies in brand management, competitive intelligence, and channel optimization rather than clinical innovation.
Brand ManagerCommercial Operations Manager
Worked on ZEGERID OTC at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.